Patents Assigned to Teligene Ltd.
  • Patent number: 11034656
    Abstract: The present application relates to maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, crystalline forms thereof, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 15, 2021
    Assignee: Teligene Ltd.
    Inventor: Dawei Zhang
  • Patent number: 10173995
    Abstract: The present invention is directed to novel pyridines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The present invention discloses compounds of Formulas I and II. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Grant
    Filed: January 11, 2014
    Date of Patent: January 8, 2019
    Assignee: Teligene Ltd.
    Inventor: Dawei Zhang
  • Patent number: 10159663
    Abstract: The present invention is directed to novel substituted macrocycles compounds, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: December 25, 2018
    Assignee: Teligene Ltd.
    Inventors: Xiaoyang Xia, Dawei Zhang
  • Publication number: 20180134683
    Abstract: The present invention is directed to novel heterocyclic compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have IDHs inhibitory activities and are useful for the treatment of Isocitrate dehydrogenases mediated diseases and conditions. Novel heterocyclic compounds disclosed herein include pyrimidines and triazines.
    Type: Application
    Filed: May 6, 2016
    Publication date: May 17, 2018
    Applicant: TELIGENE LTD.
    Inventors: Xiaoyang Xia, Dawei Zhang
  • Publication number: 20170216264
    Abstract: The present invention is directed to novel substituted macrocycles compounds, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Application
    Filed: August 18, 2015
    Publication date: August 3, 2017
    Applicant: TELIGENE LTD.
    Inventors: Xiaoyang Xia, Dawei Zhang
  • Patent number: 9388160
    Abstract: The present invention is directed to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates, prodrug, stereoisomer, tautomer, metabolite and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: July 12, 2016
    Assignee: Teligene Ltd
    Inventor: Dawei Zhang
  • Publication number: 20150353524
    Abstract: The present invention is directed to novel pyridines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The present invention discloses compounds of Formulas I and II. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Application
    Filed: January 11, 2014
    Publication date: December 10, 2015
    Applicant: Teligene Ltd
    Inventor: Dawei ZHANG
  • Publication number: 20140235658
    Abstract: The present invention is directed to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates, prodrug, stereoisomer, tautomer, metabolite and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Application
    Filed: October 12, 2012
    Publication date: August 21, 2014
    Applicant: Teligene Ltd.
    Inventor: Dawei Zhang